Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Takahiro Yamasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9793-0399; OpenAlex author ID A5019395170. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer. Last author DOI 10.1002/cam4.72202↗
  2. Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11091-y↗
  3. Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11677-6↗
  4. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. Last author DOI 10.1159/000527342↗
  5. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Last author DOI 10.1159/000511940↗
  6. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-020-07167-8↗
  7. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Co-author DOI 10.18632/oncotarget.25421↗
  8. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. Co-author DOI 10.1186/s12885-016-2744-9↗
  9. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1186/1479-5876-12-175↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Takami · 8 shared papers, 2016–2026 · strength 1.09
  2. Shuhei Shinoda · 6 shared papers, 2016–2026 · strength 0.86
  3. Isao Sakaida · 7 shared papers, 2016–2023 · strength 0.83
  4. Shogo Amano · 5 shared papers, 2018–2023 · strength 0.66
  5. Hirofumi Harima · 5 shared papers, 2016–2023 · strength 0.60
  6. Yutaka Suehiro · 4 shared papers, 2014–2026 · strength 0.52
  7. Shigeyuki Suenaga · 3 shared papers, 2021–2026 · strength 0.48
  8. Kaori Hamamoto · 2 shared papers, 2022–2026 · strength 0.37
  9. Hiroto Matsui Matsui · 3 shared papers, 2014–2022 · strength 0.26
  10. Shoko Tabara · 1 shared paper, 2026 · strength 0.26
  11. Yuko Fujimoto · 2 shared papers, 2021–2022 · strength 0.23
  12. Hiroaki Nagano · 1 shared paper, 2022 · strength 0.12
  13. Keiko Shinjo · 1 shared paper, 2022 · strength 0.12
  14. Yutaka Kondo · 1 shared paper, 2022 · strength 0.12
  15. Hiroaki Nagano · 1 shared paper, 2021 · strength 0.11
  16. Masaaki Oka · 1 shared paper, 2014 · strength 0.04
  17. Tomio Ueno · 1 shared paper, 2014 · strength 0.04
  18. Yoshitaro Shindo · 1 shared paper, 2014 · strength 0.04
  19. Nobuaki Suzuki · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.